PT-141 (Bremelanotide): What It Is Approved For and What It Isn't
Bremelanotide is one of the few peptides with a real FDA approval, and that approval is narrower than almost anyone selling PT-141 admits. Here is what it covers, what the trials showed and what it doesn't cover.
PT-141 is one of the few peptides sold online that also has a real FDA approval behind it. That is exactly why it gets misrepresented. The approval is narrow, specific and worth reading closely, because most of what is marketed as "PT-141" sits outside it.
The short version
- Bremelanotide is the drug name for PT-141. As the brand Vyleesi, it was FDA-approved in 2019.
- The approval covers one group: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), where low desire causes marked distress and isn't explained by another condition, a medication or relationship problems.
- The label says plainly that it is not indicated for postmenopausal women, for men, or to enhance sexual performance.
- In the two phase 3 trials, the improvements in desire and distress over placebo were statistically significant but modest. Nausea affected about 4 in 10 women.
- It is not appropriate for people with uncontrolled high blood pressure or known cardiovascular disease, and it interacts with oral naltrexone.
- Compounded, nasal and "research" versions are not the approved product, and in sport bremelanotide's status should be checked with your anti-doping body before use.
If you have searched for PT-141 you have probably seen it described as a "libido peptide" for anyone, a male performance aid, or a cousin of the tanning injections. Each of those descriptions contains a grain of history and a large amount of stretch. This guide sets out what the approved drug is, what the trials found, who it was never tested or approved for, and how to have a useful conversation with a clinician about low desire.
Where PT-141 came from
Bremelanotide belongs to a family of compounds that act on melanocortin receptors, a set of receptors involved in skin pigmentation, appetite, inflammation and sexual behavior. It was developed from work on melanotan II, the unapproved "tanning peptide" whose side effects we cover in Melanotan II: why dermatologists worry. Researchers noticed that compounds in this family affected sexual arousal, and the developer, Palatin Technologies, pursued that effect.
The early program was aimed at men with erectile dysfunction, using a nasal spray. It stalled. In a 2007 announcement, Palatin reported that FDA had questioned the overall efficacy results and clinical benefit in the erectile dysfunction populations studied, and had cited blood pressure increases as its greatest safety concern. Development later shifted to a self-administered injection under the skin, and to women with low sexual desire.
That history matters for one practical reason: the version of bremelanotide that reached approval is a different product, for a different population, from the one many websites still describe.
What Vyleesi is actually approved for
FDA approved Vyleesi (bremelanotide injection) in 2019. The indication on the label is precise, and each part of it does work.
- Premenopausal women. The trials enrolled premenopausal women; the average age was 39.
- Acquired HSDD, meaning desire used to be at a level the person was comfortable with and has since fallen, as opposed to lifelong low desire.
- Generalized, meaning it happens regardless of the type of stimulation, situation or partner.
- The low desire causes marked distress or interpersonal difficulty. Lower desire that doesn't bother you is not a disorder.
- It is not due to a co-existing medical or psychiatric condition, problems in the relationship, or the effects of a medication or drug.
The label then lists its limitations of use: Vyleesi is not indicated for postmenopausal women, for men, or to enhance sexual performance. Labeling specifies the dose, the route (a single-use autoinjector under the skin of the abdomen or thigh, used before anticipated sexual activity) and limits on how often it can be used. Those details are for your prescriber and pharmacist to walk through with you, not something to improvise.
Worth knowing
"On-demand" is part of what makes bremelanotide different from flibanserin (Addyi), the other FDA-approved medicine for HSDD in premenopausal women. Flibanserin is a daily tablet and is not a peptide. Both have specific safety considerations, and neither is a first step before a proper assessment of why desire has changed.
What the phase 3 trials found
The approval rested on two identical phase 3 trials, known as RECONNECT, published by Kingsberg and colleagues in Obstetrics & Gynecology in 2019. Together they enrolled more than 1,200 premenopausal women with HSDD, who used bremelanotide or placebo as needed over 24 weeks.
The two primary endpoints were changes in a desire score (from the Female Sexual Function Index) and in distress related to low desire (from the Female Sexual Distress Scale). Bremelanotide produced statistically significant improvements in both, compared with placebo, in both trials.
The size of those improvements is where honest reporting matters. The effect sizes reported were about 0.39 for desire and 0.27 for distress, conventionally described as small to moderate. A published commentary in the Journal of Psychosexual Health (Rao and Andrade, 2020) noted that the number of satisfying sexual events did not differ significantly between drug and placebo, while arguing that the effect sizes are in line with other medicines for this condition.
Put plainly: in these trials, on average, women using bremelanotide reported somewhat more desire and somewhat less distress about it than women using placebo. Some women will have noticed a meaningful change; others will not have. It is not a switch.
Side effects and who should not use it
The prescribing information is specific, and it is worth knowing before a consultation rather than after a prescription.
Common side effects
In the trials, the most common adverse reactions were nausea (about 40%), flushing (about 20%), injection site reactions (about 13%), headache (about 11%) and vomiting (about 5%). The label notes nausea tended to be most frequent with the first dose. In the open-label extension of the trials, about one in five women stopped because of adverse events.
Blood pressure
Bremelanotide causes a transient increase in blood pressure and a decrease in heart rate after each dose. In the label, the average rise was around 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after a dose and generally returning to baseline within 12 hours. That is small for a healthy person and potentially important for someone whose blood pressure is already high. The drug is contraindicated in uncontrolled hypertension or known cardiovascular disease.
Skin darkening
Because bremelanotide acts on melanocortin receptors, it can cause focal hyperpigmentation on the face, gums or breasts. The label reports it in about 1% of patients in the trials, more often in people with darker skin and with more frequent use, and notes that it did not resolve in every case.
Interactions
Bremelanotide can significantly reduce blood levels of oral naltrexone, a medicine used for alcohol and opioid use disorders. The label advises against using the two together where naltrexone is being used for those conditions. It may also slow stomach emptying, which can matter for other oral medications taken around the same time.
Be careful here
If a provider is prepared to prescribe PT-141 without checking your blood pressure, asking about heart disease, reviewing your medication list and asking whether you are premenopausal, the approved label has been ignored before you have taken a single dose. Our guide to peptide side effects and what to report covers the symptoms that should prompt a call.
What PT-141 is not approved for
Most of the online demand for PT-141 is for uses the label specifically excludes. That doesn't automatically make every such prescription wrong, because clinicians may lawfully prescribe off-label. It does mean there is no FDA-reviewed evidence of benefit or safety for those uses, and you should hear that stated plainly.
Men
Bremelanotide is not approved for men, and the erectile dysfunction program did not lead to approval. Men with low desire or erectile problems have approved, well-studied options and, just as importantly, possible underlying causes worth finding: cardiovascular disease, diabetes, medication effects, depression, and sometimes low testosterone. Our article on low testosterone symptoms explains why a blood test is a starting point rather than an answer.
Postmenopausal women
Low desire after menopause is common and real, but it was not the population studied for approval, and the causes often differ. Vaginal dryness, pain with sex, sleep disruption from night sweats and mood changes can all play a part, and several have effective treatments. We look at this in peptides for women over 40.
Performance enhancement
The label excludes it by name. People without a desire disorder were not studied, so there is nothing to say about benefit, and the side effects above still apply.
Compounded, nasal and "research" PT-141
There are three quite different things sold under the PT-141 name.
- Vyleesi, the FDA-approved autoinjector, dispensed by a pharmacy on prescription.
- Compounded bremelanotide, prepared by a compounding pharmacy for an individual patient. Compounded preparations are not FDA-approved, and federal law limits compounding of drugs that are essentially copies of a commercially available approved product. Nasal sprays and troches fall here; their absorption, dose consistency and blood pressure effects have not been evaluated the way the approved injection was.
- "Research use only" vials sold online. These are outside the pharmacy system entirely. Nobody has verified what is in them. We explain the risks in the research peptide grey market.
Rules on compounding change, and enforcement priorities shift. If the regulatory side matters to your decision, check FDA's current guidance or ask your clinician to explain where things stand today; our overview of peptide regulatory status is a good primer.
What a good consultation about low desire looks like
Low desire is rarely one thing. A careful clinician treats bremelanotide as one possible tool, and only after asking questions that a checkout page never will.
- What changed, and when? A clear timeline often points toward a cause: a new medication, a birth, a period of stress, the start of perimenopause.
- Medications. Some antidepressants, hormonal contraceptives and blood pressure medicines are associated with lower desire.
- Mood, sleep and relationships. Depression, anxiety, exhaustion and relationship strain can each lower desire, and the label excludes HSDD that is better explained by them.
- Pain or physical symptoms. Pain with sex deserves its own assessment.
- Blood pressure and heart health. Required before bremelanotide is even on the table.
- Menopausal status. Because the approval is for premenopausal women.
Sometimes the right outcome is a referral to a sex therapist or gynecologist, a change to an existing prescription, or treatment of a sleep or mood problem. Sometimes it is a prescription for the approved product. A consultation that can end in "this isn't the right medicine for you" is the kind worth paying for. If you want to talk it through, our peptide therapy consultations start with that full history, and you can book a consultation with a licensed clinician when you're ready.
Worth knowing
Competitive athletes should check bremelanotide with USADA or their sport's anti-doping body before using it, even with a prescription. Many peptides are prohibited, and substances can be caught by broad categories on the list. See peptides and drug testing.
Common questions
Is PT-141 the same as Vyleesi?
PT-141 is the research code for bremelanotide, and Vyleesi is the FDA-approved brand of bremelanotide injection. The molecule is the same; the product, its manufacturing controls and its approved use are specific to Vyleesi. Compounded or "research" products labelled PT-141 are not Vyleesi.
Does PT-141 work for men?
It is not FDA-approved for men. An earlier program in men with erectile dysfunction did not proceed to approval after FDA raised efficacy questions and cited blood pressure increases as its main safety concern. Men with desire or erection problems have other approved options, and a clinician should look for underlying causes first.
How quickly does bremelanotide work?
It is designed to be used before anticipated sexual activity rather than daily, and the label describes the timing. In the trials, results were assessed over 24 weeks, and effects on desire and distress were modest on average. Individual experience varies, and the label advises stopping if there is no improvement after a period of use.
Can people with high blood pressure use bremelanotide?
It is contraindicated in uncontrolled hypertension and known cardiovascular disease because it causes a temporary rise in blood pressure after each dose. Anyone with blood pressure concerns should have them assessed before it is considered.
Can I get PT-141 through telehealth?
A licensed clinician can assess whether bremelanotide is appropriate through a telehealth visit, including history, medications and a recent blood pressure reading. Whether a prescription follows depends entirely on that assessment. Our guide to what happens in a peptide consultation explains the process.
Talk to a licensed clinician
Reading about a treatment is not the same as knowing whether it fits your history. A consultation is a conversation about your own situation — not a sales call, and not a promise of any outcome.
Book a consultation
